Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease

OMV 佐剂嵌合体疫苗针对莱姆病的评价

• 批准号: 10672571
• 负责人: LISA MORICI
• 金额: $ 127.5万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10672571
• 关键词: Adjuvant; Antigens; Attenuated; Bite; Borrelia burgdorferi; Burkholderia; Contractor; Dose; Etiology; Evaluation; Formulation; Human; Ixodes; Lipid A; Lyme Disease; Lyme Disease Vaccines; Membrane; Mus; Preparation; Research; Safety; Schedule; Testing; Vaccine Adjuvant; Vaccines; Vesicle; efficacy evaluation; efficacy study; immunogenicity; nonhuman primate; prevent; screening; unvaccinated

The Contractor is developing Burkholderia-derived outer membrane vesicles (OMVs), containing a naturally-attenuated lipid A, as a vaccine adjuvant. This research will develop the adjuvant within the context of a vaccine to prevent Lyme disease in humans. Borrelia burgdorferi is the etiologic agent of Lyme disease, which is transmitted by the bite of Ixodes ticks. There are no currently approved vaccines that prevent Lyme disease in humans.

承包商正在开发伯克霍尔德氏菌衍生的外膜囊泡（omv），含有自然减毒的脂质a，作为疫苗佐剂。这项研究将在预防人类莱姆病的疫苗的背景下开发佐剂。伯氏疏螺旋体是莱姆病的病原，莱姆病通过蜱虫叮咬传播。目前还没有批准的预防人类莱姆病的疫苗。